Licence agreed
Sheffield University spin-out Lifestyle Choices Ltd has agreed a licence with an unnamed US reproductive diagnostics company for exclusive rights to market the company’s Plan Ahead test, which provides a measure of how many eggs a woman has in her ovaries.
The company is backed by the quoted technology commercialisation company, Biofusion plc.
The US partner will sell and distribute Plan Ahead through its network of specialty physicians. Lifestyle Choices will receive an agreed fee, on a sliding scale, per test. The product is due to be launched before the end of 2007.
Plan Ahead is a triple hormone test intended to help women to make more informed decisions about conception. It was developed by Bill Ledger, Professor of Obstetrics and Gynaecology at Sheffield University. The test measures three hormone levels in the blood, the ovarian hormones, Inhibin B and AMH, and FSH, a pituitary hormone.
The result is a predictive assessment of the number of eggs in the woman’s ovaries compared to the average range that would be expected for women of the same age. The test is accurate for up to two years ahead.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
